Revenue
No reported data
Sionna Therapeutics, Inc. (SION)
Price—Loading quote
Net income
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2023
2024
2025
Financial statements
| 2025 | 2024 | |
|---|---|---|
| Research & development | $60.3M | $57.3M |
| Operating expenses | $89.0M | $70.6M |
| Operating income | −$89.0M | −$70.6M |
| Net income | −$75.3M | −$61.7M |
| Basic EPSper diluted share | -$1.88 | -$15.99 |
| Diluted EPSper diluted share | -$1.88 | -$15.99 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 27, 2026Form 4 · 10b5-1 | Thompson Peter A.Director | SellCommon Stock · indirect | 101 | $44.49 | $4.5K | 2.67M |
| May 27, 2026Form 4 · 10b5-1 | ORBIMED ADVISORS LLC +1Director | SellCommon Stock · indirect | 101 | $44.49 | $4.5K | 2.67M |
| May 11, 2026Form 4 · 10b5-1 | Thompson Peter A.Director | SellCommon Stock · indirect | 184.6K | $46.22 | $8.53M | 2.67M |
| May 11, 2026Form 4 · 10b5-1 | ORBIMED ADVISORS LLC +1Director | SellCommon Stock · indirect | 184.6K | $46.22 | $8.53M | 2.67M |
| May 8, 2026Form 4 · 10b5-1 | Thompson Peter A.Director | SellCommon Stock · indirect | 59.8K | $44.58 | $2.66M | 2.86M |